Glenmark Pharma.
Glenmark Pharma. Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 4 strong
The short version
India business expected to grow consistently at 12%-15% annually, driven by strong brands and new product launches like Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, and BRUKINSA. Glenmark expects sustained growth, particularly driven by India with 12%-15% consistent growth projected (Page 9, 11, 12). - Upcoming product launches in India (Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, BRUKINSA) and respiratory launches in the U.S.
From Glenmark Pharma.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- India business expected to grow consistently at 12%-15% annually, driven by strong brands and new product launches like Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, and BRUKINSA.
- Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong.
- U.S. business growth supported by upcoming respiratory launches in H2 FY27, with Monroe differentiated injectables kicking in next year.
- Europe expected to grow at high single digits this year, moving towards double-digit growth with increasing focus on branded products (targeting ~60% branded revenue in 5 years).
- New oncology specialty portfolio and innovative products (e.g., ISB 2001, IGI pipeline assets 2301 and 2302) to contribute to medium- and long-term growth.
2 more points from Glenmark Pharma.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Glenmark Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Glenmark is making strategic investments to strengthen oncology commercial capabilities, especially in emerging markets, to prepare for launches of Aumolertinib, Trastu Reze, and envafolimab.
- These investments support a projected INR500-600 million revenue over 5-6 years from these oncology brands.
- The same infrastructure will be leveraged for launching ISB 2001 in the future, indicating ongoing capital commitment to innovative oncology assets.
- R&D investment remains significant, with a quarterly spend of around INR289 crores and an annual guidance of 7-8% of revenue.
2 more points from Glenmark Pharma.'s call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glenmark Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Glenmark Pharma.'s call on order book
Pro opens every point from 15K+ earnings calls
Glenmark Pharma. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.9K Cr, net profit ₹403 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glenmark Pharma.'s management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key concall takeaways from Beta Drugs Ltd's Q1 FY27…
Arthneeti Pro · Annual
Glenmark Pharma. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glenmark Pharma. Q1 FY27 results?
India business expected to grow consistently at 12%-15% annually, driven by strong brands and new product launches like Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, and BRUKINSA. Glenmark expects sustained growth, particularly driven by India with 12%-15% consistent growth projected (Page 9, 11, 12). - Upcoming product launches in India (Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, BRUKINSA) and respiratory launches in the U.S.
What is Glenmark Pharma. share price analysis?
Glenmark Pharma. currently shows a below-average growth signal. The stock trades at a P/E of 22.1 with a market cap of ₹69,072 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharma. planning capital expenditure?
Glenmark is making strategic investments to strengthen oncology commercial capabilities, especially in emerging markets, to prepare for launches of Aumolertinib, Trastu Reze, and envafolimab.
Keep Glenmark Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.